Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005

European Journal of Cancer

Volumn 43, Issue 6, 2007, Pages 974-978

  Verweij, Jaap ^a   Casali, Paolo G ^b   Kotasek, Dusan ^c   Le Cesne, Axel ^d   Reichard, Peter ^e   Judson, Ian R ^f   Issels, R ^g,h   van Oosterom, Allan T ⁱ   Van Glabbeke, Martine ^j   Blay, Jean Yves ^k  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c Adelaide Cancer Centre   (Australia)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e Section of Pathology   (Germany)

^f Royal Marsden Hospital   (United Kingdom)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h INSTITUTE OF EPIDEMIOLOGY   (Germany)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j EORTC DATA CENTER   (Belgium)

^k EDOUARD HERRIOT HOSPITAL   (France)

more..

Author keywords

Cardiotoxicity; GIST; Imatinib

Indexed keywords

IMATINIB;

ADULT; AGED; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSE COMPARISON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; PERIORBITAL EDEMA; PHASE 3 CLINICAL TRIAL; POPULATION; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33947722204     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.01.018     Document Type: Article

References (10)

1. O"Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Eng J Med 348 (2003) 994-1004
2. van Oosterom A.T., Judson I., Verweij J., et al. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupSafety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358 (2001) 1421-1423
3. Verweij J., van Oosterom A., Blay J.Y., et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39 (2003) 2006-2011
4. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (2002) 472-480
5. Verweij J., Casali P.G., Zalcberg J., et al. For the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group and the Australasian Gastrointestinal Trials Group. Progression-free survival in gastrointestinal stromal tumours with high-dose imatininb: randomized trial. Lancet 364 (2004) 1127-1134
6. Rankin C., Von Mehren M., Blanke C., et al. Dose effect of imatinib in patients with metastatic GIST - Phase III sarcoma group study S0033. J Clin Oncol 22 14S (2004) 9005 [abstract]
7. Kerkela R., Grazette L., Yacobi R., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12 (2006) 908-916
8. Park Y.H., Park H.J., Kim B.S., et al. BNP as marker of heart failure in the treatment of imatinib mesylate. Cancer Lett 243 (2006) 16-22
9. van Glabbeke M., Verweij J., Casali P.G., et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research adn Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group. Eur J Cancer 42 (2006) 2277-2285
10. Zalcberg J.R., Verweij J., Casali P.G., et al. EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group; Australasian Gastrointestinal Trials Group. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41 12 (2005) 1751-1757